Tech Company Financing Transactions
Adjuvia Therapeutics Funding Round
On 7/29/2026, Adjuvia Therapeutics landed $8 million in Seed investment from JLo Ventures and Portfolia.
Transaction Overview
Company Name
Announced On
7/29/2026
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Seed
Investors
JLo Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the submission of an Investigational New Drug (IND) application for its lead candidate, ATI-105, followed by the initiation of a Phase 1 clinical trial in healthy volunteers in Fall 2026, and a Phase 1/2 study in patients with Friedreich's ataxia in early 2027.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
953 Indiana Street
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Overview
Adjuvia Therapeutics is a clinical-stage biopharmaceutical company pioneering blood-brain barrier (BBB)-penetrant nanoparticle therapies that address mitochondrial dysfunction, the fundamental biological mechanism driving rare and chronic degenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laura Glickman
Chief Medical Officer
Gurdyal Kalsi
Chief Operating Officer
Kelly Bryant
Co-Founder
Tim Wilson
Browse more venture capital transactions:
Prev: 7/29/2026: LearnVector venture capital transaction
Next: 7/29/2026: Avant venture capital transaction
Share this article
About Our VC Transactions Data
We document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs